tradingkey.logo

Cytek Biosciences Inc

CTKB
4.620USD
+0.080+1.76%
終値 11/07, 16:00ET15分遅れの株価
590.74M時価総額
損失額直近12ヶ月PER

Cytek Biosciences Inc

4.620
+0.080+1.76%

詳細情報 Cytek Biosciences Inc 企業名

Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.

Cytek Biosciences Incの企業情報

企業コードCTKB
会社名Cytek Biosciences Inc
上場日Jul 23, 2021
最高経営責任者「CEO」Dr. Wenbin Jiang, Ph.D.
従業員数648
証券種類Ordinary Share
決算期末Jul 23
本社所在地47215 Lakeview Boulevard
都市FREMONT
証券取引所NASDAQ Global Select Consolidated
United States of America
郵便番号94538
電話番号18779229835
ウェブサイトhttps://cytekbio.com
企業コードCTKB
上場日Jul 23, 2021
最高経営責任者「CEO」Dr. Wenbin Jiang, Ph.D.

Cytek Biosciences Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
6.06M
+0.25%
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.31M
+1.00%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
99.15K
+18.50%
Dr. Philippe Busque, Ph.D.
Dr. Philippe Busque, Ph.D.
Senior Vice President, Global Sales and Services
Senior Vice President, Global Sales and Services
18.92K
+18.83%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
15.71K
--
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
15.71K
--
Mr. Michael Holder
Mr. Michael Holder
Independent Director
Independent Director
10.18K
+27.27%
Mr. William (Bill) Mccombe
Mr. William (Bill) Mccombe
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jack T. Ball, Jr.
Mr. Jack T. Ball, Jr.
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
6.06M
+0.25%
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.31M
+1.00%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
99.15K
+18.50%
Dr. Philippe Busque, Ph.D.
Dr. Philippe Busque, Ph.D.
Senior Vice President, Global Sales and Services
Senior Vice President, Global Sales and Services
18.92K
+18.83%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
15.71K
--
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
15.71K
--

収益内訳

通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Biotechnology, pharmaceutical, distributor and CRO
23.85M
52.30%
Academia and government
21.75M
47.70%
地域別USD
会社名
収益
比率
United States
23.89M
52.40%
EMEA
12.31M
26.99%
APAC
7.87M
17.25%
Other
1.53M
3.36%
事業別
地域別
事業別USD
会社名
収益
比率
Biotechnology, pharmaceutical, distributor and CRO
23.85M
52.30%
Academia and government
21.75M
47.70%

株主

更新時刻: Thu, Nov 6
更新時刻: Thu, Nov 6
株主統計
種類
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
12.03%
The Vanguard Group, Inc.
5.42%
HHLR Advisors, Ltd.
5.21%
Yan (Ming)
4.74%
Jiang (Wenbin)
4.16%
他の
68.45%
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
12.03%
The Vanguard Group, Inc.
5.42%
HHLR Advisors, Ltd.
5.21%
Yan (Ming)
4.74%
Jiang (Wenbin)
4.16%
他の
68.45%
種類
株主統計
比率
Investment Advisor
29.12%
Investment Advisor/Hedge Fund
20.84%
Individual Investor
9.28%
Hedge Fund
7.26%
Pension Fund
1.17%
Research Firm
1.00%
Bank and Trust
0.37%
Family Office
0.11%
Venture Capital
0.09%
他の
30.76%

機関投資家保有株

更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
315
75.48M
59.03%
-10.81M
2025Q2
324
88.51M
69.57%
-10.34M
2025Q1
332
90.47M
71.35%
-13.48M
2024Q4
323
90.06M
70.25%
-11.48M
2024Q3
303
87.47M
66.52%
-16.26M
2024Q2
288
88.67M
67.45%
-13.39M
2024Q1
284
98.75M
75.24%
-12.70M
2023Q4
276
96.90M
74.11%
-15.57M
2023Q3
266
97.16M
71.81%
-17.75M
2023Q2
259
98.92M
72.71%
-3.90M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
BlackRock Institutional Trust Company, N.A.
15.38M
12.09%
-1.12M
-6.80%
Jun 30, 2025
The Vanguard Group, Inc.
7.74M
6.08%
-1.86M
-19.35%
Jun 30, 2025
HHLR Advisors, Ltd.
6.66M
5.23%
--
--
Jun 30, 2025
Yan (Ming)
6.06M
4.76%
+15.29K
+0.25%
Aug 18, 2025
Jiang (Wenbin)
5.31M
4.18%
+52.68K
+1.00%
Aug 18, 2025
Topline Capital Management, LLC
5.23M
4.11%
+3.76M
+255.68%
Jun 30, 2025
Brown Capital Management, LLC
7.11M
5.59%
-353.97K
-4.74%
Jun 30, 2025
State Street Investment Management (US)
4.17M
3.28%
-208.41K
-4.76%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
3.45M
2.72%
+601.00K
+21.06%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.73M
2.15%
+42.92K
+1.60%
Jun 30, 2025
詳細を見る

関連ETF

更新時刻: Thu, Nov 6
更新時刻: Thu, Nov 6
銘柄名
比率
Invesco S&P SmallCap Health Care ETF
0.24%
Royce Quant Small-Cap Quality Value ETF
0.21%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
Avantis US Small Cap Equity ETF
0.05%
iShares S&P Small-Cap 600 Value ETF
0.05%
SPDR S&P 600 Small Cap Value ETF
0.05%
Principal U.S. Small-Cap ETF
0.04%
iShares Biotechnology ETF
0.04%
Proshares Ultra Smallcap 600
0.03%
Invesco S&P SmallCap 600 QVM Multi-factor ETF
0.03%
詳細を見る
Invesco S&P SmallCap Health Care ETF
比率0.24%
Royce Quant Small-Cap Quality Value ETF
比率0.21%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
比率0.06%
Avantis US Small Cap Equity ETF
比率0.05%
iShares S&P Small-Cap 600 Value ETF
比率0.05%
SPDR S&P 600 Small Cap Value ETF
比率0.05%
Principal U.S. Small-Cap ETF
比率0.04%
iShares Biotechnology ETF
比率0.04%
Proshares Ultra Smallcap 600
比率0.03%
Invesco S&P SmallCap 600 QVM Multi-factor ETF
比率0.03%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
種類
比率
データなし
日付
種類
比率
データなし
KeyAI